Truist Financial Cuts DaVita (NYSE:DVA) Price Target to $215.00

DaVita (NYSE:DVA) had its target price decreased by research analysts at Truist Financial from $250.00 to $215.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Truist Financial’s target price would indicate a potential upside of 19.40% from the stock’s previous close.

DVA has been the subject of a number of other reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday. Raymond James Financial set a $220.00 price objective on shares of DaVita in a research report on Friday. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Oppenheimer set a $220.00 price target on DaVita in a report on Friday. Finally, Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DaVita has a consensus rating of “Hold” and an average price target of $221.75.

DaVita Stock Performance

Shares of NYSE:DVA opened at $180.06 on Friday. The stock has a market capitalization of $11.49 billion, a price-to-earnings ratio of 14.83, a PEG ratio of 0.63 and a beta of 0.88. The stock’s 50-day simple moving average is $218.65 and its two-hundred day simple moving average is $176.48. DaVita has a 52-week low of $101.00 and a 52-week high of $247.49.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts forecast that DaVita will post 14.7 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DaVita

Institutional investors have recently bought and sold shares of the business. Root Financial Partners LLC raised its holdings in DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares during the period. Caitlin John LLC purchased a new stake in shares of DaVita during the fourth quarter worth about $34,000. Sankala Group LLC purchased a new stake in shares of DaVita during the fourth quarter worth about $39,000. Canada Pension Plan Investment Board bought a new stake in DaVita during the 2nd quarter valued at approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new position in DaVita in the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.